Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Minocycline treatment for rheumatoid arthritis: an open dose finding study.
Long term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis
Unprovoked seizures in multiple sclerosis and systemic lupus erythematosus: A population-based case-control study.
Animal Models in Neurology: Drawbacks and Opportunities.
Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Mechanism for p38α-mediated experimental autoimmune encephalomyelitis.
Food and Drug Administration briefing document for ofatumumab
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response.
Multiple sclerosis: Spinal cord grey matter loss correlates with disability in MS.
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
Transcriptomics: mRNA and alternative splicing.

Pages